MetaCap

Black Diamond Therapeutics (BDTX) vs Tenaya Therapeutics (TNYA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Black Diamond Therapeutics (BDTX) has outperformed Tenaya Therapeutics (TNYA) over the past year, losing 65.5% versus a loss of 76.7%. Over five years, BDTX leads with a -79.3% price change compared with -98.5% for TNYA. Black Diamond Therapeutics is the larger company by market cap ($75.3 million vs $65.3 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BDTX-65.53%TNYA-76.70%
+19%-31%-81%
Nov 21, 20251 yearNov 20, 2026
BDTX-81.55%TNYA-98.68%
+5%-49%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BDTX versus TNYA key metrics
MetricBDTXTNYA
Share price$1.31$0.2866
Market cap$75.28M$65.32M
1-day change-5.76%-3.99%
YTD return-46.09%-59.75%
1-year return-65.53%-76.70%
5-year return-79.30%-98.50%
EPS (TTM)$-0.77$-0.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$70.00M—
Net income (latest FY)$22.37M$-90.60M
Operating margin17.89%—
Net margin31.95%—
52-week high$3.97$1.46
52-week low$1.31$0.28
Distance from 52-week high-67.00%-80.37%
Analyst consensusnonenone
Avg. price target upside+663.36%+1016.54%
Average volume697.70K2.96M
Shares outstanding57.47M227.93M
Employees2170
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BDTX has outperformed TNYA by 11.2 percentage points over the past year.

About Black Diamond Therapeutics

BDTX stock →

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees

About Tenaya Therapeutics

TNYA stock →

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees

BDTX vs TNYA FAQ

Which is bigger, Black Diamond Therapeutics or Tenaya Therapeutics?

Black Diamond Therapeutics (BDTX) is larger, with a market capitalization of $75.28M compared with $65.32M for Tenaya Therapeutics (TNYA).

Which stock has performed better over the past year, BDTX or TNYA?

BDTX returned -65.53% over the past 12 months, compared with -76.70% for TNYA (price return, excluding dividends). Past performance does not predict future results.

Are Black Diamond Therapeutics and Tenaya Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons